Aptamer Sciences Inc Logo

Aptamer Sciences Inc

Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.

291650 | KO

Overview

Corporate Details

ISIN(s):
KR7291650000
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative aptamer-based technologies for therapeutics and diagnostics. The company leverages its proprietary integrated platforms to address unmet medical needs, primarily in oncology. Its therapeutic pipeline is centered on the ApDC™ (Aptamer-Drug Conjugate) platform, with lead candidate AST-201 advancing to clinical trials for treating GPC3-positive solid tumors like liver cancer. In the diagnostics segment, the company has developed and commercialized the AptoDetect™ platform, which includes AptoDetect™-Lung, an aptamer-based diagnostic kit for assessing lung cancer risk. Aptamer Sciences focuses on advancing its pipeline and forming strategic partnerships to commercialize its novel aptamer technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 84.4 KB
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.9 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.4 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 5.9 KB
2025-09-09 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2025-09-08 00:00
M&A Activity
경영권변경등에관한계약체결
Korean 15.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 891.5 KB
2025-07-03 00:00
Regulatory News Service
풍문또는보도에대한해명
Korean 4.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 745.9 KB
2025-04-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.2 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.5 KB

Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptamer Sciences Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.